Fig. 6

DNA methylation, gene expression, and survival analysis of P16 gene. a The β values in the 74 HCC tissues highly expressing P16 and in 41 non-tumor tissues. Statistical significance between the two groups was analyzed by Student’s t test. *. **. *** Significantly different at p < 0.05, p < 0.01, and p < 0.001 respectively. b The β values of P16 in HCC tissues of pathological stages I, II, III, and IV and non-tumor tissues. Statistical significance was analyzed by one-way ANOVA followed by Turkey-Kramer test as a post hoc comparison. * Significantly different at p < 0.05. c The expression levels of P16 in HCC tissues and non-tumor tissues. d The expression levels of P16 in HCC tissues of pathological stages I, II, III, and IV and non-tumor tissues. e Kaplan-Meier analyzes for 90 HCC patients with higher and lower expression of P16. f The expression levels of P16 in various types of cancers. Light black and dark black bars indicate expression in tumor tissues and non-tumor tissues, respectively. ACC adenoid cystic carcinoma, BLCA bladder carcinoma, BRCA breast invasive carcinoma, CESC cervical squamous cell carcinoma, CHOL cholangiocarcinoma, COAD colon adenocarcinoma, DLBC diffuse large B cell lymphoma, ESCA esophageal carcinoma, GBM glioblastoma, HNSC head-neck squamous cell carcinoma, KICH kidney chromophobe, KIRC kidney renal clear cell carcinoma, KIRP kidney renal papillary cell carcinoma, LAML acute myeloid leukemia, LGG low-grade glioma, LIHC liver hepatocellular carcinoma, LUAD lung adenocarcinoma, LUSC lung squamous cell carcinoma, OV ovarian cancer, PAAD pancreatic adenocarcinoma, PCPG pheochromocytoma and paraganglioma, PRAD prostate adenocarcinoma, READ rectum adenocarcinoma, SAC sarcoma, SKCM skin cutaneous melanoma, STAD stomach adenocarcinoma, TGCT testicular germ cell tumors, THCA thyroid cancer, THYM thymoma, UCEC uterine corpus endometrial carcinoma, UCS uterine carcinosarcoma